BB Biotech Update March 2022

With the rising inflation followed by higher interest rates investors in general seem more focused on the cost of capital which placed pressure on growth equities in January, February and the beginning of March. In the second half of March we saw some reallocation of capital into growth equities, recovering some of the losses incurred during the first quarter of 2022. BB Biotech´s share price ended the month up by 7.3% (in CHF).